CohBar, Inc.’s CEO Simon Allen to Present at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York

Senior Management Team to Participate in Hanson Wade’s Inaugural NASH Summit in Boston

MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that its CEO Simon Allen will present an overview of the Company and its clinical development program at the 1st Annual H.C. Wainwright & Co. NASH Investor Conference in New York City.

CohBar’s senior management team will also be participating in Hanson Wade’s NASH Summit in Boston April 4-6, 2017.

CohBar presentation details:

Date:     Monday, April 3, 2017
Time: 3:40 pm EDT
Location: St. Regis Hotel (Versailles Room), New York City

About H.C. Wainwright & Co.’s NASH Investor Conference
This inaugural, investor-focused event will feature presentations by public and private biotech companies that are developing therapeutic treatments for NASH, as well as panel discussions by renowned key opinion leaders in the NASH field.

About Hanson Wade’s NASH Summit
This inaugural, scientific and pharmaceutical community focused event will bring together leading researchers and drug developers in the field of liver disease to share ideas and discuss challenges and opportunities they face from drug discovery to late stage clinical development.

About NAFLD and NASH
Non-alcoholic fatty liver disease (NAFLD) is the buildup of extra fat in liver cells that is not due to alcohol consumption and tends to develop in people who are overweight or obese or have diabetes, high cholesterol or high levels of triglycerides. Non-alcoholic steatohepatitis (NASH) is a more severe form of NAFLD characterized by swelling of the liver that eventually may lead to scarring (cirrhosis), and over time to liver cancer or liver failure. NAFLD affects as much as 34% of the US population while as many as 12% of US adults may have NASH. Currently, there are no FDA approved treatments for NAFLD or NASH.

About CohBar’s Clinical Development Program
CohBar’s lead clinical development program is based on MOTS-c, a mitochondrial-derived peptide discovered in 2012 by the Company’s founders and their academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company has developed optimized analogs of the MOTS-c peptide, CB4209 and CB4211, as drug candidates for advancement into IND-enabling activities. These drug candidates have demonstrated significant therapeutic potential in preclinical models for the treatment of obesity, with additional ongoing studies to determine their therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver disease, and as an add-on to other drugs for the treatment of type 2 diabetes.

About CohBar
CohBar (OTCQX: CWBR and TSXV: COB.U) is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome, which regulate metabolism and cell death and whose biological activity declines with age. CohBar’s efforts are focused on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease, type 2 diabetes, cancer, cardiovascular and neurodegenerative disorders. To date, the Company and its founders have discovered more than 50 biologically active mitochondrial peptides.

Forward-Looking Statements
This news release contains forward-looking statements, including statements concerning the company’s plans and prospects, including statements regarding potential development of MBTs into disease therapeutics. These forward-looking statements involve a number of risks and uncertainties including the possibility of unfavorable research results and CohBar’s ability to obtain capital, retain key personnel, expand its research operations, and successfully advance its drug discovery and development programs. Additional assumptions, risks and uncertainties are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission and applicable Canadian securities regulators, which are available on our website, and at or You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this news release are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For additional company information, please visit

Investor and Media Contact:
CohBar, Inc.
Anna Schram, 650-446-7888 ext. 114

Source: CohBar, Inc.